Investor Overview

Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News

Recent News

Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas  -  6/22/2020
Grows capacity to process up to three million tests annually SAN CARLOS, Calif. , June 22, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the expansion of its laboratory facility in Austin, Texas , supporting greater More »
Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing  -  6/18/2020
Two large-scale studies evaluating use of Signatera in colorectal cancer gain early momentum SAN CARLOS, Calif. , June 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan and More »
Natera Files Patent Suit Against Progenity, Inc.  -  6/17/2020
SAN CARLOS, Calif. , June 17, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, filed suit today against Progenity, Inc. for infringing six patents: U.S. Patents  9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242 (the "Asserted More »
Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights  -  6/1/2020
Quantifying background cfDNA increases accuracy of dd-cfDNA testing SAN CARLOS, Calif. , June 1, 2020 /PRNewswire/ --   Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the launch of a novel technique to enhance results from the Prospera More »
Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA  -  5/26/2020
New research on background cell-free DNA to refine transplant rejection risk SAN CARLOS, Calif. , May 26, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its Prospera donor-derived cell-free DNA More »
Event

Upcoming Events

More events are coming soon.
Events

Past events

Date
Title

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.